Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,299 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06176989RecruitingPhase 2
Enasidenib for IDH2-mutated sinonasal and skull base tumors
This trial tests an oral targeted therapy called enasidenib for people with rare head and neck cancers that have an IDH2 gene mutation. The goal is to see if this drug can shrink or slow the growth of these tumors.
Bethesda, MarylandAges 18–120 - NCT05759923RecruitingPhase 1
Study of OATD-02 for hard-to-treat solid tumors
This early (first-in-human) study tests whether OATD-02 is safe and tolerable, and whether it shows any anti-cancer activity. It is for adults with certain advanced or metastatic cancers that have already been treated with the standard options.
Bydgoszcz, Kuyavian-Pomeranian VoivodeshipAges 18 years+ - NCT04541082RecruitingPhase 1
Oral ONC206 for recurrent brain and spinal tumors
This early-phase study tests an oral medicine called ONC206 in adults with recurrent, rare brain or spinal cord tumors. The goal is to find a safe dose and look for signs the treatment can shrink or control the cancer.
Bethesda, MarylandAges 18 years+ - NCT04322318RecruitingPhase 2
Study of combination chemotherapy for Wilms tumor in children
This Phase 2 trial tests combination chemotherapy for children with certain types of Wilms tumor—either newly diagnosed diffuse anaplastic Wilms tumor or favorable Wilms tumor that has come back. The goal is to see how well the treatment controls the tumor and is tolerable for children.
Birmingham, AlabamaAges Up to 30 years - NCT04185038RecruitingPhase 1
CAR T therapy through a catheter for pediatric brain tumors
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
Seattle, WashingtonAges 1–26 - NCT07851636Recruiting
Fast genetic testing to guide treatment for rare brain tumors
This trial tests a new way to pick treatments for rare brain tumors that have come back. Doctors will quickly analyze your tumor's genes and test drugs in the lab to find the best option for you.
Washington D.C., District of ColumbiaAges Up to 45 years - NCT07650240RecruitingPhase 2
PSMA Therapy and Hormone Treatment for Early-Stage Prostate Cancer Spread
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
Rochester, MinnesotaAges 18 years+ - NCT07447076RecruitingPhase 2
New treatments for recurrent ATRT brain tumor
This trial tests new treatments for children and young adults whose ATRT brain tumor has come back or grown. It aims to find if these therapies can help control the tumor.
San Francisco, CaliforniaAges 1–39 - NCT07087002RecruitingPhase 1
GPC2-CAR T cells for children and young adults with relapsed medulloblastoma
This trial tests a new type of cell therapy called GPC2-CAR T cells for children and young adults whose medulloblastoma or related brain tumor has come back or not responded to standard treatment. The goal is to see if these specially designed immune cells can find and attack the tumor.
Palo Alto, CaliforniaAges 1–30 - NCT06441331RecruitingPhase 1
Lu-177 edotreotide for children with SSTR-positive tumors
This trial tests a radioactive drug called Lu-177 edotreotide for children with a certain type of tumor (SSTR-positive) that hasn't responded to other treatments. The goal is to find the right dose and see how safe it is.
San Francisco, CaliforniaAges 2–18 - NCT06295965Recruiting
Blood changes and cancer therapy study
This study looks at why some people develop blood disorders after cancer treatment. It monitors changes in blood cells to better predict and prevent these problems.
Seattle, WashingtonAges Any age - NCT06276491RecruitingPhase 1
Safety study of an investigational drug for advanced cancer with the CLDN6 marker
This trial tests an investigational drug for people with advanced solid tumors, especially ovarian, fallopian tube, peritoneal, endometrial, or germ cell cancers that have a specific marker called CLDN6. The goal is to see if the drug is safe and tolerable.
Duarte, CaliforniaAges 15 years+ - NCT01898416RecruitingPhase 2
5-ALA by mouth to reduce regrowth of desmoid tumors
This Phase 2 trial tests whether taking a medicine called 5-ALA by mouth after treatment can lower how often desmoid tumors come back in the same area. If you have a desmoid tumor that can be removed and you meet safety criteria, this study may help determine whether 5-ALA is effective and safe for you.
Tel Aviv, IsraelAges 18 years+ - NCT06273176Recruiting
Surgery with or without brain mapping for recurrent glioblastoma
This study is testing whether using a special brain-mapping technique during surgery helps people with recurrent glioblastoma. It compares standard surgery to surgery with mapping to see if it leads to better outcomes for tumors near important brain areas.
San Francisco, CaliforniaAges Up to 90 years - NCT07628634RecruitingEarly Phase 1
Testing a Low-Methionine Diet in Solid Tumor Patients
This early-stage study explores whether eating a diet low in methionine (a natural amino acid found in protein) might help people with advanced solid tumors. Researchers will track how this dietary change affects blood levels and may improve treatment outcomes alongside standard cancer care.
Orange, CaliforniaAges 18 years+ - NCT07593820RecruitingPhase 1
CAR-T Cell Study for Advanced HER2-Positive Cancers
This early-stage trial tests a new type of immune cell therapy called CAR-T cells, which are designed to recognize and attack cancer cells that have a protein called HER2. The cells are made from your own immune cells, trained in the laboratory, and given back to you. The study evaluates how safe the treatment is and whether it can shrink tumors.
Barcelona, CataloniaAges 18 years+ - NCT07399769RecruitingPhase 1/Phase 2
MSLN CAR-T therapy for advanced solid tumors
This trial tests a new immune cell therapy called MSLN CAR-T for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help if your cancer has not responded to standard treatment and tests positive for a protein called mesothelin (MSLN).
Shenzhen, Other (Non U.s.)Ages 18–75 - NCT07340164RecruitingPhase 2
Trastuzumab deruxtecan vs standard care for recurrent ovarian cancer
This trial compares a targeted drug called trastuzumab deruxtecan to standard treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment with a PARP inhibitor. The study is for patients whose tumors show a certain level of a protein called HER2 on their surface.
Seoul, SeoulAges 18 years+ - NCT07136181RecruitingPhase 1/Phase 2
Study of NBM-BMX for advanced uveal melanoma that has spread
This trial tests a new oral drug, NBM-BMX, for people with metastatic uveal melanoma (melanoma of the eye that has spread). It aims to see if the drug is safe and effective. You may join if you have already tried some treatments, including tebentafusp if you are HLA-A*02:01 positive.
Scottsdale, ArizonaAges 18 years+ - NCT01793168Recruiting
Rare disease registry and history study
This study keeps a registry (a structured list) of people with rare diseases and may also track how the condition changes over time. It can help researchers better understand rare illnesses and find gaps in care, which may improve future treatments.
Sioux Falls, South DakotaAges Any age - NCT06773481RecruitingPhase 1
BC008-1A injection for recurrent grade 4 glioma
This trial tests a new injection called BC008-1A for people with a grade 4 glioma (a type of brain cancer) that has come back after standard treatment. The goal is to see if the drug can help control the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06835218Recruiting
Prostate cancer real-world evidence registry
This study collects information from men with prostate cancer to better understand how different treatments work in real life. It follows patients when they start a new treatment and can help improve future care.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT06654336RecruitingPhase 2
Targeted therapy with or without hormone therapy for prostate cancer that has spread a little
This trial tests whether targeting the spots where cancer has returned with radiation or surgery, with or without hormone therapy, can help control prostate cancer that has come back in a few places after previous treatment.
Hamilton, OntarioAges 18 years+ - NCT06362369RecruitingPhase 1/Phase 2
Oral 7HP349 with immunotherapy for advanced solid tumors
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
Aurora, ColoradoAges 18 years+
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,299 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.